1-5 of 5
Mrinal Gounder
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors

J. Andrew Livingston, Jean-Yves Blay, Jonathan Trent, Claudia Valverde, Mark Agulnik, Mrinal Gounder, Axel Le Cesne, Meredith McKean, Michael J. Wagner, Silvia Stacchiotti, Samuel Agresta, Alfonso Quintás-Cardama, Sarah A. Reilly, Kathleen Healy, Denice Hickman, Tina Zhao, Alex Ballesteros-Perez, Alexis Khalil, Michael P. Collins, Jessica Piel, Kim Horrigan, Ariel Lefkovith, Scott Innis, Alexander J. Lazar, Gregory M. Cote, Andrew J. Wagner
Journal: Clinical Cancer Research
Clin Cancer Res (2024)
https://doi.org/10.1158/1078-0432.CCR-24-2583
Published: 11 December 2024
View article titled, A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors
Open the PDF for A Phase 1 Study of FHD-609, a Heterobifunctional Degrader of Bromodomain-Containing Protein 9, in Patients With Advanced Synovial Sarcoma or SMARCB1-Deficient Tumors in another window
Includes: Supplementary data
Journal Articles

Abstract PR012: Targeted sequencing of 2,138 bone and soft tissue sarcomas reveals commonly altered pathways, subtype-independent genetic clusters, and potential therapeutic targets

Benjamin A. Nacev, Francisco Sanchez-Vega, Shaleigh Smith, Cristina Antonescu, Evan Rosenbaum, Hongyu Shi, Cerise Tang, Nicholas Socci, Satshil Rana, Rodrigo Gularte-Merida, Ahmet Zehir, Mrinal Gounder, Timothy Bowler, Anisha Luthra, Bhumika Jadeja, Azusa Okada, Jonathan Strong, Jake Stoller, Jason Chan, Ping Chi, Sandra D'Angelo, Mark Dickson, Ciara Kelly, Mary Louise Keohan, Sujana Movva, Katherine Thornton, Paul Meyers, Leonard Wexler, Emily Slotkin, Julia Glade Bender, Neerav Shukla, Martee Hensley, John Healey, Michael La Quaglia, Kaled Alektiar, Aimee Crago, Sam Yoon, Brian Untch, Sarah Chiang, Narasimhan Agaram, Meera Hameed, Michael Berger, David Solit, Nikolaus Schultz, Marc Ladanyi, Samuel Singer, William Tap
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): PR012.
https://doi.org/10.1158/1557-3265.SARCOMAS22-PR012
Published: 15 September 2022
View article titled, Abstract PR012: Targeted sequencing of 2,138 bone and soft tissue sarcomas reveals commonly altered pathways, subtype-independent genetic clusters, and potential therapeutic targets
Journal Articles

Abstract A028: Growth factor signaling and kinase inhibitors regulate oncogenesis in desmoid fibromatosis by modulating activity of the beta-catenin transcription target ABL1

Jia Hu, Anthony Villano, Rachael O'Connor, Yuliy Rozenberg, Alankrta Venkatesh, Mrinal Gounder, Nicholas Socci, Samuel Singer, Meera Hameed, Aimee M. Crago
Journal: Clinical Cancer Research
Clin Cancer Res (2022) 28 (18_Supplement): A028.
https://doi.org/10.1158/1557-3265.SARCOMAS22-A028
Published: 15 September 2022
View article titled, Abstract A028: Growth factor signaling and kinase inhibitors regulate oncogenesis in desmoid fibromatosis by modulating activity of the beta-catenin transcription target ABL1
Journal Articles

HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome

Evan Rosenbaum, Kenneth Seier, Chaitanya Bandlamudi, Mark Dickson, Mrinal Gounder, Mary L. Keohan, Ping Chi, Ciara Kelly, Sujana Movva, Benjamin Nacev, Noemi Simeone, Mark Donoghue, Emily K. Slotkin, Li-Xuan Qin, Cristina R. Antonescu, William D. Tap, Sandra P. D'Angelo
Journal: Clinical Cancer Research
Clin Cancer Res (2020) 26 (20): 5448–5455.
https://doi.org/10.1158/1078-0432.CCR-20-0832
Published: 15 October 2020
View article titled, HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome
Open the PDF for HLA Genotyping in Synovial Sarcoma: Identifying HLA-A*02 and Its Association with Clinical Outcome in another window
Includes: Supplementary data
Journal Articles

The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials

Alexia Iasonos, Mrinal Gounder, David R. Spriggs, John F. Gerecitano, David M. Hyman, Sarah Zohar, John O'Quigley
Journal: Clinical Cancer Research
Clin Cancer Res (2012) 18 (19): 5179–5187.
https://doi.org/10.1158/1078-0432.CCR-12-0726
Published: 30 September 2012
View article titled, The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials
Open the PDF for The Impact of Non–Drug-Related Toxicities on the Estimation of the Maximum Tolerated Dose in Phase I Trials in another window
Includes: Supplementary data